Associated factors for quality of life in patients with progressive supranuclear palsy

doi:10.3969/j.issn.1672-6731.2021.05.014

Abstract

Abstract:

Objective To explore the associated factors for quality of life in patients with progressive supranuclear palsy (PSP). Methods A total of 218 PSP patients were included from January 2012 to December 2019. Demographic and clinical data were collected. The quality of life was evaluated by the 39-Item Parkinson's disease Questionnaire (PDQ-39). The Progressive Supranuclear Palsy Rating Scale (PSPRS) was used to assess the severity of PSP related motor and non-motor symptoms, while the Non-Motor Symptoms Scale (NMSS) was used to elevate the non-motor symptoms, Hamilton Depression Rating Scale-24 (HAMD -24), Hamilton Anxiety Rating Scale (HAMA), Lille Apathy Rating Scale (LARS), Frontal Assessment Battery (FAB), and Montreal Cognitive Assessment (MoCA) were used. The Pearson and partial correlation followed by the multiple linear regression were used to explore the correlates of the PDQ-39 score. Results Correlation analysis indicated that the PDQ-39 score was positively correlated with disease duration (r=0.301, P=0.000), Charlson Comorbidity Index (CCI; r=0.147, P=0.031), levodopa equivalent daily dose (LEDD; r=0.225, P=0.001), and scores for the PSPRS (r=0.551, P=0.000), NMSS (r=0.484, P=0.000), HAMD-24 (r=0.515, P=0.000), HAMA (r=0.439, P=0.000) and LARS (r=0.476, P=0.000), but was negatively correlated with scores of FAB (r=-0.325, P=0.000) and MoCA (r=-0.355, P=0.000). Multiple linear stepwise regression model indicated that the PDQ-39 score was significantly associated with female (P=0.021), longer disease duration (P=0.026), higher LEDD (P=0.008), higher PSPRS score (P=0.000), higher NMSS score (P=0.002), higher HAMD-24 score (P=0.004), and higher LARS score (P=0.000). Conclusions Female, longer disease duration, higher LEDD, and more severe motor and non-motor symptoms contribute to the reduced quality of life in patients with PSP. Our study is beneficial to the clinical management of patients with PSP.

Key words: Supranuclear palsy, progressive, Quality of life, Linear models

摘要：

目的探讨进行性核上性麻痹患者生活质量的相关因素。方法连续纳入2012年1月至2019年12月共218例进行性核上性麻痹患者，采集其社会人口学和临床资料，采用39项帕金森病调查表（PDQ-39）评估生活质量，进行性核上性麻痹评价量表（PSPRS）评估运动症状和非运动症状，非运动症状量表（NMSS）评估非运动症状，汉密尔顿抑郁量表24项（HAMD-24）、汉密尔顿焦虑量表（HAMA）和里尔淡漠评定量表（LARS）评估情绪，额叶功能评价量表（FAB）评估额叶功能，蒙特利尔认知评价量表（MoCA）评估认知功能。对PDQ-39评分与社会人口学和各项量表评分行相关分析以及线性数量关系的验证。结果相关分析显示，PDQ-39评分与病程（r=0.301，P=0.000）、查尔森合并症指数（CCI）评分（r=0.147，P=0.031）、左旋多巴日等效剂量（r=0.225，P=0.001）、PSPRS评分（r=0.551，P=0.000）、NMSS评分（r=0.484，P=0.000）、HAMD-24评分（r=0.515，P=0.000）、HAMA评分（r=0.439，P=0.000）和LARS评分（r=0.476，P=0.000）呈正相关，而与FAB评分（r=-0.325，P=0.000）和MoCA评分（r=-0.355，P=0.000）呈负相关。多因素线性逐步回归分析显示，女性（P=0.021）、病程（P=0.026）、左旋多巴日等效剂量（P=0.008），以及PSPRS评分（P=0.000）、NMSS评分（P=0.002）、HAMD-24评分（P=0.004）和LARS评分（P=0.000）均与PDQ-39评分存在线性回归关系。结论女性、长病程、高左旋多巴日等效剂量以及严重的运动症状和非运动症状均与进行性核上性麻痹患者生活质量存在线性回归关系，应引起临床医师的高度重视。

关键词: 核上麻痹, 进行性, 生活质量, 线性模型

CHEN De-zhi, OU Ru-wei, WEI Qian-qian, HOU Yan-bing, ZHANG Ling-yu, LIU Kun-cheng, JIANG Zheng, LIN Jun-yu, LIU Jiao, YANG Tian-mi, YANG Jing, SHANG Hui-fang. Associated factors for quality of life in patients with progressive supranuclear palsy[J]. Chinese Journal of Contemporary Neurology and Neurosurgery, 2021, 21(5): 411-415.

陈德智, 欧汝威, 魏倩倩, 侯炎冰, 张灵语, 刘坤成, 蒋政, 林隽羽, 刘焦, 杨天米, 杨静, 商慧芳. 进行性核上性麻痹患者生活质量相关分析[J]. 中国现代神经疾病杂志, 2021, 21(5): 411-415.

/ / Recommend / Download Citations

URL: http://journal11.magtechjournal.com/cjcnn/EN/10.3969/j.issn.1672-6731.2021.05.014

http://journal11.magtechjournal.com/cjcnn/EN/Y2021/V21/I5/411

References

[1] Schrag A, Ben-Shlomo Y, Quinn NP. Prevalence of progressive supranuclear palsy and multiple system atrophy:a cross-sectional study[J]. Lancet, 1999, 354:1771-1775.
[2] Litvan I, Agid Y, Calne D, Campbell G, Dubois B, Duvoisin RC, Goetz CG, Golbe LI, Grafman J, Growdon JH, Hallett M, Jankovic J, Quinn NP, Tolosa E, Zee DS. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome):report of the NINDS-SPSP international workshop[J]. Neurology, 1996, 47:1-9.
[3] Gerstenecker A, Duff K, Mast B, Litvan I; ENGENE -PSP Study Group. Behavioral abnormalities in progressive supranuclear palsy[J]. Psychiatry Res, 2013, 210:1205-1210.
[4] Brown RG, Lacomblez L, Landwehrmeyer BG, Bak T, Uttner I, Dubois B, Agid Y, Ludolph A, Bensimon G, Payan C, Leigh NP; NNIPPS Study Group. Cognitive impairment in patients with multiple system atrophy and progressive supranuclear palsy[J]. Brain, 2010, 133(Pt 8):2382-2393.
[5] Ou R, Wei Q, Hou Y, Zhang L, Liu K, Xu X, Gu X, Lin J, Jiang Z, Liu J, Song W, Cao B, Shang H. Suicidal and death ideation in patients with progressive supranuclear palsy and corticobasal syndrome[J]. J Affect Disord, 2020, 276:1061-1068.
[6] Ou R, Song W, Wei Q, Chen K, Cao B, Hou Y, Zhao B, Shang H. Characteristics of nonmotor symptoms in progressive supranuclear palsy[J]. Parkinsons Dis, 2016:ID9730319.
[7] Pekmezovi? T, Je?menica-Luki? M, Petrovi? I, Špica V, Tomi? A, Kosti? VS. Quality of life in patients with progressive supranuclear palsy:one-year follow-up[J]. J Neurol, 2015, 262:2042-2048.
[8] Colosimo C, Morgante L, Antonini A, Barone P, Avarello TP, Bottacchi E, Cannas A, Ceravolo MG, Ceravolo R, Cicarelli G, Gaglio RM, Giglia L, Iemolo F, Manfredi M, Meco G, Nicoletti A, Pederzoli M, Petrone A, Pisani A, Pontieri FE, Quatrale R, Ramat S, Scala R, Volpe G, Zappulla S, Bentivoglio AR, Stocchi F, Trianni G, Del Dotto P, Simoni L, Marconi R; PRIAMO STUDY GROUP. Non-motor symptoms in atypical and secondary parkinsonism:the PRIAMO study[J]. J Neurol, 2010, 257:5-14.
[9] Lee CN, Kim M, Lee HM, Jang JW, Lee SM, Kwon DY, Park KW, Koh SB. The interrelationship between non-motor symptoms in Atypical Parkinsonism[J]. J Neurol Sci, 2013, 327:15-21.
[10] Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index[J]. J Clin Epidemiol, 1994, 47:1245-1251.
[11] Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of levodopa dose equivalency reporting in Parkinson's disease[J]. Mov Disord, 2010, 25:2649-2653.
[12] Jenkinson C, Peto V, Fitzpatrick R, Greenhall R, Hyman N. Self-reported functioning and well-being in patients with Parkinson's disease:comparison of the short-form health survey (SF-36) and the Parkinson's Disease Questionnaire (PDQ-39)[J]. Age Ageing, 1995, 24:505-509.
[13] Golbe LI, Ohman-Strickland PA. A clinical rating scale for progressive supranuclear palsy[J]. Brain, 2007, 130(Pt 6):1552-1565.
[14] Wang G, Hong Z, Cheng Q, Xiao Q, Wang Y, Zhang J, Ma JF, Wang XJ, Zhou HY, Chen SD. Validation of the Chinese non-motor symptoms scale for Parkinson's disease:results from a Chinese pilot study[J]. Clin Neurol Neurosurg, 2009, 111:523-526.
[15] Hamilton M. Development of a rating scale for primary depressive illness[J]. Br J Soc Clin Psychol, 1967, 6:278-296.
[16] Clark DB, Donovan JE. Reliability and validity of the Hamilton Anxiety Rating Scale in an adolescent sample[J]. J Am Acad Child Adolesc Psychiatry, 1994, 33:354-360.
[17] Leentjens AF, Dujardin K, Marsh L, Martinez-Martin P, Richard IH, Starkstein SE, Weintraub D, Sampaio C, Poewe W, Rascol O, Stebbins GT, Goetz CG. Apathy and anhedonia rating scales in Parkinson's disease:critique and recommendations[J]. Mov Disord, 2008, 23:2004-2014.
[18] Rothlind JC, Brandt J. A brief assessment of frontal and subcortical functions in dementia[J]. J Neuropsychiatry Clin Neurosci, 1993, 5:73-77.
[19] Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I, Cummings JL, Chertkow H. The Montreal Cognitive Assessment, MoCA:a brief screening tool for mild cognitive impairment[J]. J Am Geriatr Soc, 2005, 53:695-699.
[20] Holden SK, Koljack CE, Prizer LP, Sillau SH, Miyasaki JM, Kluger BM. Measuring quality of life in palliative care for Parkinson's disease:a clinimetric comparison[J]. Parkinsonism Relat Disord, 2019, 65:172-177.
[21] Winter Y, Spottke AE, Stamelou M, Cabanel N, Eggert K, Höglinger GU, Sixel-Doering F, Herting B, Klockgether T, Reichmann H, Oertel WH, Dodel R. Health-related quality of life in multiple system atrophy and progressive supranuclear palsy[J]. Neurodegener Dis, 2011, 8:438-446.
[22] Hashizume Y. Gender issues and Japanese family-centered caregiving for frail elderly parents or parents-in-law in modern Japan:from the sociocultural and historical perspectives[J]. Public Health Nurs, 2000, 17:25-31.
[23] Kao HF, McHugh ML. The role of caregiver gender and caregiver burden in nursing home placements for elderly Taiwanese survivors of stroke[J]. Res Nurs Health, 2004, 27:121-134.
[24] Koh EK, Koh CK. Caring for older adults:the parables in Confucian texts[J]. Nurs Sci Q, 2008, 21:365-368.
[25] Schrag A, Selai C, Davis J, Lees AJ, Jahanshahi M, Quinn N. Health-related quality of life in patients with progressive supranuclear palsy[J]. Mov Disord, 2003, 18:1464-1469.
[26] Ou R, Liu H, Hou Y, Wei Q, Cao B, Zhao B, Shang H. Executive dysfunction, behavioral changes and quality of life in Chinese patients with progressive supranuclear palsy[J]. J Neurol Sci, 2017, 380:182-186.
[27] Schrag A, Selai C, Quinn N, Lees A, Litvan I, Lang A, Poon Y, Bower J, Burn D, Hobart J. Measuring quality of life in PSP:the PSP-QoL[J]. Neurology, 2006, 67:39-44.
[28] Coughlin DG, Litvan I. Progressive supranuclear palsy:advances in diagnosis and management[J]. Parkinsonism Relat Disord, 2020, 73:105-116.
[29] Winter Y, Stamelou M, Cabanel N, Sixel-Döring F, Eggert K, Höglinger GU, Herting B, Klockgether T, Reichmann H, Oertel WH, Dodel R, Spottke AE. Cost-of-illness in multiple system atrophy and progressive supranuclear palsy[J]. J Neurol, 2011, 258:1827-1834.

Please choose a citation manager

Content to export